Background
Methods
Study aims
Primary objective
Secondary objectives
-
To compare the toxicity profile of CCD with that of CVD, overall and specifically with respect to peripheral neuropathy
-
To explore the non-inferiority of CCD without maintenance as compared to CVD for longer-term outcome measure of PFS
-
To further summarise the activity of CCD as compared to CVD with regard to:
-
Complete response at 24 weeks
-
Overall response at 24 weeks and within 12 months
-
Maximum response within 12 months
-
Maximum response overall
-
Time to maximum response
-
Duration of response
-
Overall survival
-
Time to next treatment
-
To determine the proportion of participants with a negative minimal residual disease (MRD) status at the end of initial treatment phase (24 weeks of treatment) in both the CVD and CCD arms and to correlate MRD-negativity at the end of the initial treatment phase (24 weeks) with PFS for all participants
-
To assess the effect of maintenance Carfilzomib on MRD status at 6 months and at 12 months post second randomisation
-
To correlate treatment outcomes (Complete response CR, overall response rate ORR) and PFS with genetic subgroups
-
To summarise treatment compliance.
Study design
Sample size
-
≥ Very good partial response (VGPR)
-
Progression-free survival
Recruitment Process
Inclusion criteria for initial randomisation |
DISEASE RELATED |
- Diagnosed with symptomatic MM (according to IMWG 2003 criteria) and requiring therapy for first relapse or primary refractory disease. (Participants previously immunofixation negative who are now immunofixation positive need to demonstrate a greater than 5 g/l absolute increase in paraprotein to be eligible for inclusion). |
- Participants with measurable disease as defined by one or more of the following criteria (assessed within 21 days prior to randomisation): |
o Serum paraprotein ≥5 g/L (For IgA participants whose disease can only be reliably measured by serum quantitative immunoglobulin (IgA): ≥ 7.5 g/L) |
o Urine Bence Jones Protein: ≥200 mg/24 h |
o Serum LC assay: Involved FLC level ≥100 mg/L, provided serum FLC ratio is abnormal |
DEMOGRAPHIC |
- Age ≥18 years |
- Life expectancy ≥6 months |
- Eastern Cooperative Oncology Group (ECOG) performance status 0–2 |
LABORATORY |
- Adequate hepatic function, with alanine transaminase (ALT) or aspartate transaminase (AST) <3 times the upper limit of normal and serum direct bilirubin ≤17 μmol/L (1 mg/100 ml) within 14 days prior to randomisation |
- Absolute neutrophil count (ANC) ≥1.0 × 109/L within 14 days prior to randomisation. Growth factor support is not permitted. ANC ≥ 0.8 x 109/L is allowed for participants with racial neutropenia. |
- Haemoglobin ≥8 g/dL (80 g/L) within 14 days prior to randomisation (participants may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines) |
- Platelet count ≥75 × 109/L (≥50 × 109/L if myeloma involvement in the bone marrow is > 50 %) within 14 days prior to randomisation. Platelet support is not permitted |
- Creatinine clearance (CrCl) ≥ 20 mL/min or plasma creatinine ≤120 μmol/L within 14 days prior to randomisation, either measured or calculated using a standard formula (e.g. Cockcroft and Gault) |
ETHICAL/OTHER |
- Written informed consent |
- Female participants of child-bearing potential must have a negative pregnancy test prior to treatment and agree to use dual methods of contraception for the duration of the study and for 30 days following completion of study. Male participants must also agree to use a barrier method of contraception for the duration of the study and for 30 days following completion of study if sexually active with a female of child-bearing potential. |
Exclusion criteria for initial randomisation |
DISEASE RELATED |
- Non-secretory multiple myeloma |
- Extramedullary plasmacytoma (without evidence of myeloma) |
- Received therapy for their first relapsed or primary refractory disease other than local radiotherapy, therapeutic plasma exchange, or dexamethasone up to a maximum of 200 mg. (Radiotherapy sufficient to alleviate or control pain or local invasion is permitted). |
- Previous bortezomib therapy is permitted, providing participant was not refractory (achieved at least a PR, and no disease progression within 6 months of last dose of bortezomib) |
- Previous carfilzomib therapy |
CONCURRENT CONDITIONS |
- Pregnant or lactating females |
- Major surgery within 21 days prior to randomisation |
- Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomisation |
- Known human immunodeficiency virus infection (testing is not required for the trial) |
- Active hepatitis B or C infection |
- Unstable angina or myocardial infarction within 6 months prior to randomisation, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless participant has a pacemaker, history of torsade de pointe, QTc prolongation (>450 msec), LVEF <40 |
- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomisation |
- Previous or concurrent malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localised transitional cell carcinoma of the bladder or benign tumours of the adrenal or pancreas |
- Significant neuropathy (Grades 3–4, or Grade 2 with pain) within 14 days prior to randomisation |
- Participants with haemorrhagic cystitis |
- Any history or known hypersensitivity to any of the study medications or excipients |
- Participants undergoing active treatment for infiltrative lung disease |
- Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and anti-platelet options, antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment |
- Contraindication to a programme of oral or IV hydration |
- Participants with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomisation |
- Any other clinically significant medical disease or condition that, in the Investigator’s opinion, may interfere with protocol adherence or a participant’s ability to give informed consent |
Randomisation
Inclusion criteria for maintenance randomisation |
- Completed at least 24 weeks of CCD treatment in line with the protocol (must have received a minimum of 5 cycles and achieved a maximum response to initial therapy). |
- No evidence of disease progression |
- Adequate hepatic function, with ALT or AST <3 times the upper limit of normal and serum direct bilirubin ≤42.5 μmol/L (2.5 mg/100 ml) within 14 days prior to randomisation |
- Absolute neutrophil count (ANC) ≥1.0 × 109/L within 14 days prior to randomisation. Growth factor support received in the previous cycle of treatment is permissible. |
- Haemoglobin ≥8 g/dL (80 g/L) within 14 days prior to randomisation (participants may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines) |
- Platelet count ≥75 × 109/L (≥50 × 109/L if myeloma involvement in the bone marrow is >50 %) within 14 days prior to randomisation. Platelet support received in the previous cycle of treatment is permissible. |
- Creatinine clearance (CrCl) ≥20 mL/min or plasma creatinine ≤120 μmol/L within 7 days prior to randomisation, either measured or calculated using a standard formula (eg, Cockcroft and Gault) |
- Female participants of child-bearing potential must have a negative pregnancy test prior to treatment and agree to use dual methods of contraception for the duration of the study and for 30 days following completion of study. Male participants must also agree to use a barrier method of contraception for the duration of the study and for 30 days following completion of study if sexually active with a female of child-bearing potential. |
Exclusion criteria for maintenance randomisation |
- Uncontrolled hypertension or uncontrolled diabetes |
- Any other clinically significant medical disease or condition that, in the Investigator’s opinion, may interfere with protocol adherence |
- Pregnant or lactating females |
- Significant neuropathy (Grades 3–4, or Grade 2 with pain) |
Intervention
Trial assessments
Outcome measures
Secondary endpoint | Main comparison(s) | Analysis method(s) |
---|---|---|
Key secondary: proportion of participants experiencing ≥ grade 3 neuropathy or ≥ grade 2 neuropathy with pain during initial treatment | (a) vs. (b) | [S] Logistic regression |
(i) Total time spent at each grade of toxicity for ≥ grade 3 neuropathy or ≥ grade 2 neuropathy with pain during initial treatment | (a) vs. (b) | [NFT] Descriptive summaries |
(ii) Complete response rate 24 weeks post initial randomisation | (a) vs. (b) | [NI] Logistic regression |
(iii) Overall response rate 24 weeks post initial randomisation | (a) vs. (b) | [NI] Logistic regression |
(iv) Proportion of participants achieving MRD negative disease at the end of initial treatment | (a) vs. (b) | [NI] Logistic regression |
(v) MRD status of participants at 6 and 12 months following second randomisation and alteration in MRD status | (c) vs. (d) | [S] Logistic regression |
(vi) PFS by MRD status at the end of initial treatment | MRD -ve vs. MRD + ve | [S] Kaplan-Meier & log-rank test, Cox PH |
(vii) Overall response rate within 12 months of initial randomisation | (c) vs. (d), (a) vs. (e) | [S] Logistic regression |
(viii) Maximum response within 12 months of initial randomisation | (c) vs. (d), (a) vs. (e) | [NFT] Descriptive summaries |
(ix) Maximum response overall | (c) vs. (d), (a) vs. (e) | [NFT] Descriptive summaries |
(x) Time to maximum response | (c) vs. (d), (a) vs. (e) | [S] Kaplan-Meier & log-rank test, Cox PH |
(xi) Duration of response | (c) vs. (d), (a) vs. (e) | [S] Kaplan-Meier & log-rank test, Cox PH |
(xii) Overall survival | (c) vs. (d), (a) vs. (e) | [S] Kaplan-Meier & log-rank test, Cox PH |
(xiii) Time to next treatment | (c) vs. (d), (a) vs. (e) | [NFT] Kaplan-Meier; Cumulative Incidence Functions (competing risks) |
(xiv) Toxicity overall, and per cycle of treatment (initial and maintenance treatment) | (a) vs. (b), (c) vs. (d) | [NFT] Descriptive summaries, graded by Common Terminology Criteria for Adverse Events V4.0 |
(xv) Treatment compliance | (a) vs. (b), (c) vs. (d) | [NFT] Descriptive summaries |
(xvi) Safety | (a) vs. (b), (c) vs. (d) | [NFT] Descriptive summaries |